William Parrish, MD
Family Medicine · Bremen, GANPI 1609880707
Payments from drug & device makers
Across 278 payments — averaging $16.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$662
- Pfizer$619
- Amgen$297
- Johnson & Johnson$279
- Lilly USA, LLC$249
- AbbVie$240
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,50399%
- Education$511%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 40 | $662 |
| Pfizer | 38 | $619 |
| Amgen | 16 | $297 |
| Johnson & Johnson | 16 | $279 |
| Lilly USA, LLC | 10 | $249 |
| AbbVie | 24 | $240 |
| AstraZeneca | 16 | $232 |
| GSK | 16 | $231 |
| Supernus Pharmaceuticals, Inc. | 13 | $216 |
| Upsher-smith Laboratories LLC | 9 | $184 |
| Amarin Pharma, Inc. | 11 | $182 |
| Boehringer Ingelheim | 10 | $178 |
| Astellas Pharma US Inc | 8 | $144 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $142 |
| Phathom Pharmaceuticals, Inc. | 5 | $127 |
| Novartis | 6 | $102 |
| Sanofi-aventis U.S. LLC | 3 | $62 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $59 |
| Sumitomo Pharma America, Inc. | 3 | $55 |
| Bayer | 2 | $47 |
| Smith+Nephew | 3 | $45 |
| Mannkind Corporation | 3 | $44 |
| Merck | 3 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $24 |
| Abbott | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Shire North American Group Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVOKANA$106
How this compares
$4,555 in reported general payments places this provider in the 80th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 601 | $530,630 |
| OzempicSemaglutide | 339 | $376,367 |
| MounjaroTirzepatide | 292 | $329,251 |
| JardianceEmpagliflozin | 239 | $199,396 |
| FarxigaDapagliflozin Propanediol | 263 | $176,247 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 195 | $167,034 |
| XareltoRivaroxaban | 115 | $113,455 |
| TrulicityDulaglutide | 85 | $107,799 |
| MyrbetriqMirabegron | 122 | $81,657 |
| LinzessLinaclotide | 126 | $75,242 |
| EntrestoSacubitril/Valsartan | 59 | $60,810 |
| XifaxanRifaximin | 12 | $35,983 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 41 | $34,814 |
| Repatha SureclickEvolocumab | 49 | $34,137 |
| GemtesaVibegron | 61 | $32,722 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $619 | $530,630601 claims |
| Lilly USA, LLCMounjaro, Trulicity | $249 | $437,050377 claims |
| Novo NordiskOzempic, Rybelsus | $662 | $398,127356 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Synjardy Xr | $178 | $238,322313 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arexvy | $231 | $236,462367 claims |
| AstraZenecaFarxiga | $232 | $176,247263 claims |
| AbbVieLinzess, Ubrelvy, Vraylar, Qulipta | $240 | $135,162172 claims |
| Johnson & JohnsonXarelto, Invokana | $279 | $132,564126 claims |
| Astellas Pharma US IncMyrbetriq | $144 | $81,657122 claims |
| NovartisEntresto | $102 | $60,81059 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $142 | $35,98312 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $62 | $34,81441 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Bremen
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.